Tscan Therapeutics, INC DEF 14A proxy statements
Proxy statements, covering the matters put to shareholders at the annual meeting — board elections, auditor ratification and executive pay.
NASDAQ
TScan Therapeutics has issued its 2026 proxy statement, seeking shareholder approval for director elections, auditor ratification, and a significant increase in authorized common stock.
NASDAQ
TScan Therapeutics will hold its annual stockholder meeting on June 30, 2025, to vote on the election of directors and the ratification of its accounting firm.
NASDAQ
TScan Therapeutics will hold its 2025 Annual Meeting of Stockholders virtually on June 30, 2025, to elect directors and ratify the appointment of its independent accounting firm.
NASDAQ
DEFA14A: TScan Therapeutics Sets Date for 2024 Annual Meeting, Outlines Key Proposals for Stockholder Vote
TScan Therapeutics has scheduled its 2024 Annual Meeting for June 12, 2024, and is seeking stockholder votes on the election of directors, ratification of the accounting firm, and approval of an amended equity incentive plan.
NASDAQ
TScan Therapeutics is holding its 2024 Annual Meeting of Stockholders on June 12, 2024, to vote on the election of directors, ratification of the independent auditor, and approval of an amended equity incentive plan.